title: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
authors: Jose Luis
authors: JL
authors: Zamorano
authors: Patrizio
authors: P
authors: Lancellotti
authors: Daniel
authors: D
authors: Rodriguez Muñoz
authors: Victor
authors: V
authors: Aboyans
authors: Riccardo
authors: R
authors: Asteggiano
authors: Maurizio
authors: M
authors: Galderisi
authors: Gilbert
authors: G
authors: Habib
authors: Daniel J
authors: DJ
authors: Lenihan
authors: Gregory Y H
authors: GYH
authors: Lip
authors: Alexander R
authors: AR
authors: Lyon
authors: Teresa
authors: T
authors: Lopez Fernandez
authors: Dania
authors: D
authors: Mohty
authors: Massimo F
authors: MF
authors: Piepoli
authors: Juan
authors: J
authors: Tamargo
authors: Adam
authors: A
authors: Torbicki
authors: Thomas M
authors: TM
authors: Suter
mesh_terms: D026683:Advisory Committees; D000970:Antineoplastic Agents / Q000009:adverse effects; D000073116:Cancer Survivors; D002309:Cardiology; D066126:Cardiotoxicity / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects; D009369:Neoplasms / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects; D012955:Societies, Medical; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A
keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance